 |
|
|
 |
|
Quick Facts
|
|
If a close relative has prostate cancer, a man's risk of the disease more than doubles.
|
|
|
|
|
|
|
|
|
|
This site provides helpful information on TRELSTAR® LA, TRELSTAR®
Depot and prostate cancer. TRELSTAR LA and TRELSTAR Depot are a type of drug known
as a luteinizing hormone releasing hormone (LHRH) agonist used for the treatment
of advanced prostate cancer.
TRELSTAR is conveniently provided in two formulations, TRELSTAR LA
and
TRELSTAR Depot. (Throughout this site when reference
could apply to both or either formulations it will be simply stated as TRELSTAR.
When reference is to the specific formulation only it will be stated as TRELSTAR
LA or TRELSTAR Depot).
After skin cancer, prostate cancer is the second most common cancer in men in the
U.S., and is the third leading cause of death due to cancer in men. Today, however,
more men are surviving prostate cancer than ever before.
When a man is diagnosed with prostate cancer it could be an emotionally and physically
challenging time. As you work with your doctor, we hope that this site helps you
better understand prostate cancer and the course of treatment using TRELSTAR.
|
|
|
|
|
Indications and Usage
TRELSTAR® Depot and TRELSTAR®
LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR
Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy
or estrogen administration are either not indicated or unacceptable to the patient. |
|
|
|
Safety Information
|
|
The most commonly reported adverse events associated with the use of TRELSTAR®
Depot/TRELSTAR® LA included hot flushes (58.6%/73.0%), skeletal pain
(12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%),
and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or
may become pregnant as well as patients who are hypersensitive to triptorelin, other
LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock
and angioedema have been received since 1986 (global experience) . As with all LHRH
agonists, triptorelin causes an initial transient increase in testosterone levels.
Patients may experience the onset or exacerbation of symptoms during this period,
including bone pain, neuropathy, hematuria, spinal cord compression, or urethral
or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or
urinary tract obstruction should be closely observed. |
|
|
|
